Shots:

• Autobahn acquires global IP- development- and regulatory rights to ASP3652 to strengthen its brain-targeting chemistry platform. The addition of ASP3652 will accelerate the delivery of next-generation brain-targeting prodrugs for CNS disorders- particularly MS
• ASP3652 complements Autobahn’s brain-targeting chemistry platform- which uses FAAH-mediated prodrug conversion to enable the delivery of small molecules across the BBB. The company may develop ASP3652 in combination with multiple pipeline programs- including Autobahn’s TRβ agonists for MS
• ASP3652 is a FAAH inhibitor- previously been evaluated across 10 clinical studies in ~200 patients

  Ref: BUSINESS WIRE | Image: BioSpace